相关实验视频

Updated: Jun 30, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

在3个月的杜拉格卢提德治疗后,评估身体组成的变化

Shuqin Chen¹, Xuepeng Wang², Yong Jin³

¹Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China.

Diabetes, metabolic syndrome and obesity : targets and therapy

|March 20, 2024

概括

对于超重/肥胖2型糖尿病患者的杜拉古德治疗减少了身体脂肪和体重,而没有肌肉或骨损失. 身体脂肪减少与改善的HbA1c水平相关.

科学领域:

内分泌学在内分泌学.
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

类似葡萄糖类1受体激动剂 (GLP-1RA) 促进减肥,影响身体组成.
关于杜拉格卢提德对中国2型糖尿病患者体质组成的影响的数据有限.

研究的目的:

调查杜拉格卢类药物治疗对超重/肥胖的中国2型糖尿病患者的身体组成的影响.
探索身体成分变化与血糖控制 (HbA1c) 之间的关系.

主要方法:

一组70名超重/肥胖2型糖尿病 (T2DM) 患者接受杜拉格卢提德治疗.
在治疗3个月前和之后测量体重,内脏脂肪面积 (VFA),身体脂肪 (BF),瘦身量 (LBM),骨肌量 (SMM) 和骨矿物质质 (BMQ).
相关性和多重线性回归分析,以评估HbA1c变化和身体组成变化之间的关联.

主要成果:

杜拉古类药物治疗导致BW,VFA,BF,LBM,SMM和水含量显著降低.
瘦体质量百分比 (LBMP) 和骨肌肉质量百分比 (SMMP) 显著增加;骨矿物质质量 (BMQ) 保持不变.
在BF的百分比变化和HbA1c的百分比变化 (p=0.002) 之间发现了显著的独立关联.

结论:

在T2DM患者中,杜拉格卢提德有效地降低了身体脂肪和体重,而不会影响肌肉或骨质.
改善的血糖控制,以HbA1c降低为指标,与杜拉格卢提德治疗期间的身体脂肪减少独立相关.
这些发现支持dulaglutide在管理这个患者群体的身体组成和血糖控制方面的临床实用性.

关键词:

身体脂肪质量身体脂肪质量糖尿病糖尿病患者糖尿病患者杜拉格卢胺是什么意思肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖内脏脂肪是什么?内脏脂肪是什么?

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Murine Model of Vertical Sleeve Gastrectomy

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...